These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 8202047)
21. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. Nichols CR; Breeden ES; Loehrer PJ; Williams SD; Einhorn LH J Natl Cancer Inst; 1993 Jan; 85(1):36-40. PubMed ID: 7677934 [TBL] [Abstract][Full Text] [Related]
22. Acute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on Intergroup Rhabdomyosarcoma Study III: an interim report. Heyn R; Khan F; Ensign LG; Donaldson SS; Ruymann F; Smith MA; Vietti T; Maurer HM Med Pediatr Oncol; 1994; 23(2):99-106. PubMed ID: 8202048 [TBL] [Abstract][Full Text] [Related]
23. Acute myelogenous leukemia after treatment for malignant germ cell tumors in children. Schneider DT; Hilgenfeld E; Schwabe D; Behnisch W; Zoubek A; Wessalowski R; Göbel U J Clin Oncol; 1999 Oct; 17(10):3226-33. PubMed ID: 10506623 [TBL] [Abstract][Full Text] [Related]
24. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Linassier C; Barin C; Calais G; Letortorec S; Brémond JL; Delain M; Petit A; Georget MT; Cartron G; Raban N; Benboubker L; Leloup R; Binet C; Lamagnère JP; Colombat P Ann Oncol; 2000 Oct; 11(10):1289-94. PubMed ID: 11106118 [TBL] [Abstract][Full Text] [Related]
25. Treatment of children with epipodophyllotoxin-induced secondary acute myeloid leukemia. Sandler ES; Friedman DJ; Mustafa MM; Winick NJ; Bowman WP; Buchanan GR Cancer; 1997 Mar; 79(5):1049-54. PubMed ID: 9041170 [TBL] [Abstract][Full Text] [Related]
27. Epipodophyllotoxins in the treatment of childhood cancer. Rivera GK; Pui CH; Santana VM; Pratt CB; Crist WM Cancer Chemother Pharmacol; 1994; 34 Suppl():S89-95. PubMed ID: 8070034 [TBL] [Abstract][Full Text] [Related]
28. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. Hawkins MM; Wilson LM; Stovall MA; Marsden HB; Potok MH; Kingston JE; Chessells JM BMJ; 1992 Apr; 304(6832):951-8. PubMed ID: 1581717 [TBL] [Abstract][Full Text] [Related]
29. The MLL (11q23) and AF-4 (4q21) genes disrupted in t(4;11) acute leukemia: molecular and clinical studies. Hilden JM; Kersey JH Leuk Lymphoma; 1994 Jul; 14(3-4):189-95. PubMed ID: 7950907 [TBL] [Abstract][Full Text] [Related]
30. A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide. Takeda K; Shinohara K; Kameda N; Ariyoshi K Int J Hematol; 1998 Feb; 67(2):179-86. PubMed ID: 9631585 [TBL] [Abstract][Full Text] [Related]
31. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. Winick NJ; McKenna RW; Shuster JJ; Schneider NR; Borowitz MJ; Bowman WP; Jacaruso D; Kamen BA; Buchanan GR J Clin Oncol; 1993 Feb; 11(2):209-17. PubMed ID: 8426196 [TBL] [Abstract][Full Text] [Related]
32. Chemotherapy-related - late occurring - Philadelphia chromosome in AML, ALL and CML. Similar events related to treatment with DNA topoisomerase II inhibitors? Pedersen-Bjergaard J; Brøndum-Nielsen K; Karle H; Johansson B Leukemia; 1997 Sep; 11(9):1571-4. PubMed ID: 9305614 [TBL] [Abstract][Full Text] [Related]
33. Is age an independent risk factor for chemically induced acute myelogenous leukemia in children? Pyatt DW; Aylward LL; Hays SM J Toxicol Environ Health B Crit Rev; 2007; 10(5):379-400. PubMed ID: 17687725 [TBL] [Abstract][Full Text] [Related]
34. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. Kollmannsberger C; Hartmann JT; Kanz L; Bokemeyer C J Cancer Res Clin Oncol; 1998; 124(3-4):207-14. PubMed ID: 9619748 [TBL] [Abstract][Full Text] [Related]
35. A comparative analysis of alkylating agent and epipodophyllotoxin-related leukemias. Ellis M; Ravid M; Lishner M Leuk Lymphoma; 1993 Sep; 11(1-2):9-13. PubMed ID: 8220158 [TBL] [Abstract][Full Text] [Related]
36. Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Andersen MK; Christiansen DH; Jensen BA; Ernst P; Hauge G; Pedersen-Bjergaard J Br J Haematol; 2001 Sep; 114(3):539-43. PubMed ID: 11552977 [TBL] [Abstract][Full Text] [Related]
37. Chromosomal abnormalities in secondary MDS and AML. Relationship to drugs and radiation with specific emphasis on the balanced rearrangements. Andersen MK; Johansson B; Larsen SO; Pedersen-Bjergaard J Haematologica; 1998 Jun; 83(6):483-8. PubMed ID: 9676019 [TBL] [Abstract][Full Text] [Related]
38. Secondary acute myeloblastic leukemia in a child with acute lymphoblastic leukemia treated with epipodophyllotoxins. Ozbek N; Cetin M; Tuncer AM; Yetgin S Turk J Pediatr; 1995; 37(3):279-82. PubMed ID: 7502369 [TBL] [Abstract][Full Text] [Related]
39. Risk of acute myelogenous leukaemia and myelodysplasia following cancer treatment. van Leeuwen FE Baillieres Clin Haematol; 1996 Mar; 9(1):57-85. PubMed ID: 8730551 [TBL] [Abstract][Full Text] [Related]
40. [A case of secondary leukemia in anaplastic seminoma patient treated with long-term chemotherapy]. Kamai T; Touma T; Masuda H; Hyouchi N; Okuno T; Yonese J; Fukuda H; Tachibana Y; Ishiwata D Nihon Hinyokika Gakkai Zasshi; 1996 May; 87(5):875-9. PubMed ID: 8691713 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]